Introduction {#s1}
============

Over the past few years, the use of microarray technologies has contributed to the identification of new markers for the diagnosis and prognosis of human tumors. Cancer research usually involves the study of a single class of tumor and the corresponding normal tissue. Increasing the number of binary studies does not necessarily improve the relevance of the molecular signature. Thus, a meta-analysis comparing 40 types of cancer in various tissues relative to their normal counterpart allowed the identification of a common signature essential to carcinogenesis but may fail to distinguish between different classes of tumor affecting a given organ, which may therefore have specific prognoses [@pone.0007632-Rhodes1]. Moreover, the same signature may also appear in a variety of other cellular contexts such as inflammatory processes.

Thyroid nodules are extremely common in the adult population, but less than 20% of the nodules are malignant [@pone.0007632-Hundahl1]. Papillary thyroid carcinoma (PTC), diagnosed on the basis of characteristic nuclear features, is the most frequent malignant thyroid tumor. According to the 2004 WHO report, the diagnosis of minimal invasive follicular thyroid carcinoma (FTC) is problematic because of its morphological and molecular similarities to benign follicular thyroid adenoma (FTA) [@pone.0007632-Yeh1]. Moreover, atypical or oncocytic features render the differential diagnosis of follicular tumors difficult on histologic examination and call for new molecular or biological markers [@pone.0007632-Lacroix1], [@pone.0007632-Giordano1]. To date, microarray analyses of thyroid tumors have essentially compared two classes of tissue [@pone.0007632-Barden1]--[@pone.0007632-Weber1]. These studies have either searched for specific markers by comparing a particular class of thyroid tumor to the corresponding normal tissue, or looked for markers of malignancy by examining the most frequent benign and malignant classes of thyroid tumor (usually the FTA and PTC classes). The predictive accuracy of the markers identified is therefore rather limited with regard to tumors belonging to other classes. For example, the CITED1 gene, which was claimed to be a significant marker distinguishing PTC from normal tissue [@pone.0007632-Huang1] turned out to be less specific when data from FTC samples were included [@pone.0007632-Aldred1]. Furthermore, this gene did not even figure among the 42 best PTC marker genes detected by a meta-analysis that included benign tumors [@pone.0007632-Eszlinger1]. Meta-analyses may increase not only the number of classes required to define more relevant markers but also increase the imbalance in the representation of some classes. In a recent analysis, cross-validated marker genes from 21 studies differentiated benign from malignant thyroid tissues [@pone.0007632-Griffith1]. However, the majority of these were pertinent to the diagnosis of PTC since these thyroid cancers accounted for more than 40% of the samples studied. This highlights the bias due to the recruitment of thyroid samples for microarray studies and the consequent failure in identifying classifiers for clinical applications despite the large number of analyses exploited.

Few studies have simultaneously compared more than four types of thyroid tissue [@pone.0007632-Giordano1], [@pone.0007632-Finley1]--[@pone.0007632-Yukinawa1]. In one of these [@pone.0007632-Fontaine1], we were able to refine the diagnosis of tumors of uncertain malignancy by the simultaneous analysis of eight types of thyroid tissue. These promising results encouraged further research on relevant markers of thyroid tumors, taking into account more classes and subclasses of interest, as some authors have recommended [@pone.0007632-Eszlinger2]. In the present study, we have explored gene-expression signatures from the majority of the differentiated follicular pathologies of thyroid tissue. We have used published data or data available from the Gene Expression Omnibus (GEO) of the U. S. National Center for Biotechnology Information, as well as specifically generated data, to simultaneously analyze several datasets containing information on various pathologies, including datasets with many histological subclasses. Our analysis, covering the major subtypes of thyroid tissue, may be expected to enhance microarray data concerning thyroid tumors and lead to the definition of more reliable tissue-specific markers for thyroid lesions.

Results {#s2}
=======

We have simultaneously analyzed 347 thyroid tissue samples from six datasets ([Table 1](#pone-0007632-t001){ref-type="table"}). The Fontaine dataset, generated by our own laboratory [@pone.0007632-Fontaine1], comprised 166 thyroid tissue samples, i.e. about half the total number of samples.
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###### Datasets, classes and samples.

![](pone.0007632.t001){#pone-0007632-t001-1}

  ---------------------------------- ---------- --------------------------------- ------------------------------ ------------------------------ ------------------------------ -------------------------------------- --------------------------------------
  *Datasets*                                         *Fontaine et al. 2008*           *Giordano et al.2006*            *Weber et al.2005*            *Jarzab et al. 2005*                 *He et al. 2005*                     *Reyes et al. 2006*
  *Microarray platform*                          Single channel cDNA microarrays   Affymetrix GeneChip HG U133A   Affymetrix GeneChip HG U133A   Affymetrix GeneChip HG U133A   Affymetrix GeneChip HG U133 Plus 2.0   Affymetrix GeneChip HG U133 Plus 2.0
  *(Probes)*                                                *(9,216)*                       *(22,283)*                     *(22,283)*                     *(22,283)*                         *(54,681)*                             *(54,681)*
  *Tissue samples*                    *Symbol*                 166                              93                             24                             32                                 18                                     14
  Wild Type tissue                       WT                    24                               4                              \-                             16                                 9                                      7
  Autoimmune Thyroiditis                 AT                     5                               \-                             \-                             \-                                 \-                                     \-
  Grave\'s Disease                       GD                     5                               \-                             \-                             \-                                 \-                                     \-
  Follicular Thyroid Adenoma            FTA                    26                               10                             12                             \-                                 \-                                     \-
  Microfollicular Thyroid Adenoma       FTAb                   17                               \-                             \-                             \-                                 \-                                     \-
  Multi Nodular Goitre                  MNG                    24                               \-                             \-                             \-                                 \-                                     \-
  Follicular Thyroid Carcinoma          FTC                     3                               \-                             6                              \-                                 \-                                     \-
  * FTC with PAX8/PPARγ fusion*         FTC+                   \-                               7                              \-                             \-                                 \-                                     \-
  * FTC without PAX8/PPARγ fusion*      FTC-                   \-                               6                              \-                             \-                                 \-                                     \-
  Oncocytic Thyroid Adenoma             OTA                    30                               7                              \-                             \-                                 \-                                     \-
  Oncocytic Thyroid Carcinoma           OTC                     4                               8                              6                              \-                                 \-                                     \-
  Oncocytic Tumour of Uncertain         OTUM                    5                               \-                             \-                             \-                                 \-                                     \-
  Malignancy                                                                                                                                                                                                          
  Papillary Thyroid Carcinoma           PTC                    13                               51                             \-                             16                                 9                                      7
  Tumour of Uncertain Malignancy        TUM                    10                               \-                             \-                             \-                                 \-                                     \-
  ---------------------------------- ---------- --------------------------------- ------------------------------ ------------------------------ ------------------------------ -------------------------------------- --------------------------------------

Molecular classification of thyroid pathologies {#s2a}
-----------------------------------------------

To analyze the global classification of the follicular thyroid lesions in the Fontaine dataset, we defined the centroid of each class of tissue by a composite signature of mean gene-expression levels. The hierarchical clustering of the class centroids ([Figure 1A](#pone-0007632-g001){ref-type="fig"}) revealed three groups. The first group comprised benign thyroid lesions and normal tissues (green boxes for FTA, MNG, WT, AT, and GD); the second contained malignant lesions (red boxes for FTC, TUM and PTC); and the third included oncocytic tumors and microfollicular adenomas (blue boxes for FTAb, OTUM, OTA and OTC). These groups, supported by a high robustness index of 0.938 and a discrepancy index of 0.337, are respectively referred to as the 'benign', 'malignant' and 'oncocytic' groups. The three groups, cross-validated in the Giordano dataset ([Figure 1C](#pone-0007632-g001){ref-type="fig"}), presented almost perfect robustness ( = 1) and discrepancy indices ( = 0.001). This dataset showed a highly correlated oncocytic group (OTA, OTC, correlation \>0.6) and a group of malignant tumors (PTC, FTC+). The third group, predominantly composed of benign tumors and normal tissues (WT, FTA), also included the FTC- group.

![Molecular classification of thyroid tissues.\
The centroid signatures of the thyroid tissues were compared to each other in the Fontaine dataset generated by our laboratory [@pone.0007632-Fontaine1], and compared to the Giordano dataset [@pone.0007632-Giordano1]. Centroids were defined as the mean gene-expression signature of each tissue class over all the genes. Panel A shows the hierarchical clustering of the tissues in the Fontaine dataset. The dendrogram can be cut into three robust branches (black circles) defining three groups of classes. The groups contain benign lesions and normal tissue (green boxes), malignant tumors (red boxes), or oncocytic tumors and microfollicular adenomas (blue boxes). Panel B shows pairwise correlation coefficients between the tissue classes from the Fontaine dataset. The heatmap represents a symmetrical matrix of color-coded correlation coefficients. Tissue classes are ordered as in the hierarchical clustering and marked with the same three colors (green, red and blue). Panel C shows the hierarchical clustering of the tissues in the Giordano dataset. The dendrogram can be cut into three robust branches (black circles) defining three groups of classes. The groups contain heterogeneous lesions and normal tissue (green boxes), malignant tumors (red boxes), or oncocytic tumors (blue boxes). The two datasets show three groups containing similar tissue classes. WT: wild type tissue; PTC: papillary thyroid carcinoma; FTA: macrofollicular thyroid adenoma; FTAb: microfollicular thyroid adenoma; GMN, multinodular goiter; FTC: follicular thyroid carcinoma (FTC+: with Pax8/PPARγ translocation; FTC-: without Pax8/PPARγ translocation); OTA: oncocytic thyroid adenoma; OTC: oncocytic thyroid carcinoma; TUM: tumor of uncertain malignancy; OTUM: oncocytic tumor of uncertain malignancy; GD: Grave\'s disease; and AT: autoimmune thyroïditis.](pone.0007632.g001){#pone-0007632-g001}

We computed the prediction accuracy for the benign, malignant and oncocytic groups of thyroid tissue classes as defined above. The signature of each group was trained *versus* all the other samples, and its accuracy was compared with the predictive accuracy of individual lesions ([Table 2](#pone-0007632-t002){ref-type="table"}). In both datasets, the positive accuracy for each group was greater than the best accuracy reported for an individual lesion within the group. The high proportion of PTC (79%) in the malignant group from the Giordano dataset may explain the good accuracy for this group despite the rate of discrepancy shown in the [Figure 1C](#pone-0007632-g001){ref-type="fig"}. The separation of the samples into three groups on the basis of class similarities led to improved sample prediction in the two datasets.

10.1371/journal.pone.0007632.t002

###### Prediction of samples by considering three groups of tissue classes. Values can be compared to the range of accuracies for individual lesions that composed each group.
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                     Fontaine dataset   Giordano dataset         
  ----------------- ------------------ ------------------ ------ ------------
  Benign group             0,79            0.11--0.71      0,76   0.31--0.47
  Malignant group          0,69            0.24--0.67      0,93   0.93--0.94
  Oncocytic group          0,75            0.02--0.64      0,86   0.52--0.62

The matrix of 66 pairwise correlation coefficients between the classes ([Figure 1B](#pone-0007632-g001){ref-type="fig"}) allowed a detailed observation of the similarities and dissimilarities in the Fontaine dataset. All the classes in the benign/normal group were positively correlated with each other. Some pairs of classes were highly correlated (correlation coefficient \>0.4), e.g. FTA with MNG, and AT with GD. All the classes in the malignant group were positively correlated with each other. The TUM class had a stronger correlation with PTC than with FTC (respectively 0.354 and 0.274). This similarity between TUM and PTC has previously been demonstrated within this dataset and with independent samples [@pone.0007632-Fontaine1]. In the oncocytic group, the classes of oncocytic tumors were positively correlated with each other, except for the FTAb class. Finally, we were able to identify 220 non-redundant genes for the molecular classification of each of the 11 subcategories of follicular thyroid pathologies explored ([Table 3](#pone-0007632-t003){ref-type="table"}).

10.1371/journal.pone.0007632.t003

###### Classifier genes from the Fontaine dataset (n = 220 genes).
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  Symbol           Clone ID   Class   Cross validation support (%)   Parametric p-value   t-value   Fold-change
  --------------- ---------- ------- ------------------------------ -------------------- --------- -------------
  ABCB9             36371      AT                 100                     1,00E-07         6,81        3,28
  SEP-02            729542     AT                 100                     2,67E-01         −1,11       0,75
  SEP-05            448163     AT                 100                     1,00E-07         7,03        4,96
  AAAS              740617     AT                  99                     3,00E-07         5,36        3,34
  ABCA3             52740      AT                  97                     4,99E-01         0,68        1,13
  ABCA8             284828     AT                  97                     1,86E-01         −1,33       0,74
  ABCB1            1837488     AT                  97                     2,26E-01         −1,22       0,72
  ABCB8             238705     AT                  97                     3,51E-01         −0,94       0,84
  ABCC3             208097     AT                  96                     1,54E-01         1,43        1,64
  ABCF2            1086914     AT                  96                     1,00E-07         6,91        3,37
  BATF             1929371     AT                  83                     1,00E-07         10,52       6,03
  C18orf51          742649     AT                  62                     1,00E-07         9,87        7,47
  CARD11            665651     AT                  46                     1,00E-07         10,85       4,72
  CBFA2T2           43629      AT                  39                     1,00E-07         10,18       10,03
  CD38             1352408     AT                  29                     1,00E-07         10,18       7,22
  CD79A            1056782     AT                  25                     1,00E-07         11,14       8,58
  CD79B             155717     AT                  25                     1,00E-07         11,91       10,51
  CXCL6            2108870     AT                  14                     1,00E-07         10,13       4,29
  EPPB9             668454     AT                  7                      1,00E-07         9,67        9,03
  DKFZp667B0210    1844689     AT                  3                      1,00E-07         9,30        4,83
  PLXNB2           1420676     FTA                 65                     6,00E-07         5,21        1,70
  TBC1D17           739955     FTA                 62                     4,00E-07         5,27        1,56
  ZNF76             745003     FTA                 59                     8,00E-07         5,15        1,51
  KIAA1196          738938     FTA                 52                     1,40E-06         5,01        1,52
  ASGR1             25883      FTA                 48                     1,25E-05         4,51        1,75
  BCL2L11           300194     FTA                 42                     6,00E-06         4,68        1,42
  DAP               725371     FTA                 41                     6,20E-06         4,67        1,51
  CABIN1           1844968     FTA                 40                     1,12E-05         4,53        1,59
  FLJ14981          24532      FTA                 31                     1,84E-04         3,83        1,50
  RAD51L1           295412     FTA                 30                     4,23E-05         4,21        1,66
  TSPAN1            376003     FTA                 26                     3,52E-05         4,25        1,57
  IMAGE:745465      745465     FTA                 25                     2,58E-02         2,25        1,24
  PLCG1            1174287     FTA                 25                     8,36E-05         −4,04       0,67
  COL18A1           359202     FTA                 24                     3,20E-05         4,28        1,60
  RPS6KA2           22711      FTA                 23                     3,77E-05         4,24        1,57
  CaMKIINalpha      173820     FTA                 22                     9,52E-04         3,37        1,35
  KLF1              208991     FTA                 16                     3,01E-03         3,01        1,49
  BAT3              24392      FTA                 13                     8,11E-04         3,41        1,42
  PDK4              487379     FTA                 11                     1,00E-02         −2,61       0,70
  IMAGE:24065       24065      FTA                 6                      4,52E-04         −3,58       0,75
  KRTHB5            364569    FTAb                 86                     1,00E-07         6,02        1,94
  METRN             487475    FTAb                 86                     1,00E-07         5,68        2,15
  DCI               667892    FTAb                 74                     6,00E-07         5,19        1,63
  IFI30             740931    FTAb                 68                     4,90E-06         −4,73       0,41
  ALCAM             172828    FTAb                 64                     1,21E-05         −4,51       0,68
  ADAMTS2           364844    FTAb                 55                     1,61E-04         3,86        1,41
  ETF1              146976    FTAb                 54                     1,12E-04         3,96        1,54
  TP53I11           667514    FTAb                 44                     1,22E-04         3,94        1,94
  IMAGE:487086      487086    FTAb                 42                     1,52E-04         −3,88       0,67
  IMAGE:666315      666315    FTAb                 35                     5,63E-04         3,52        1,52
  GRB10             564994    FTAb                 33                     1,80E-04         3,83        1,42
  ISG20             740604    FTAb                 33                     3,51E-05         −4,26       0,60
  SPARC             267358    FTAb                 33                     1,09E-04         3,97        1,47
  HAS3              667533    FTAb                 28                     1,07E-04         3,97        1,52
  USP13             666007    FTAb                 20                     9,96E-05         3,99        1,56
  KRT4             1173570    FTAb                 13                     2,87E-04         3,71        1,65
  LHFP              591534    FTAb                 9                      2,24E-03         −3,11       0,74
  PCDHB15           730593    FTAb                 9                      1,06E-03         −3,33       0,74
  TPM2              740620    FTAb                 9                      9,35E-03         2,63        1,45
  DKFZp434M202      743118    FTAb                 2                      5,77E-03         −2,80       0,76
  C22orf9           667250     FTC                 89                     2,00E-07         −5,43       0,34
  SUCLG2            687551     FTC                 83                     7,00E-07         −5,18       0,27
  LAPTM4A           726684     FTC                 77                     4,00E-07         −5,26       0,24
  KIAA1576          743426     FTC                 76                     1,00E-07         5,70        3,33
  NR2F2             72744      FTC                 65                     2,60E-06         4,87        3,11
  CHST3             665327     FTC                 62                     2,90E-06         −4,85       0,32
  PAI-RBP1          236055     FTC                 55                     5,30E-06         −4,71       0,29
  IMAGE:729896      729896     FTC                 54                     3,00E-07         5,34        3,22
  ZBTB16           2467442     FTC                 52                     4,72E-05         4,18        4,68
  ZNF364            471834     FTC                 52                     5,80E-06         −4,69       0,39
  GHITM             25077      FTC                 50                     5,30E-06         −4,71       0,31
  LRP8              415554     FTC                 49                     1,43E-04         3,90        2,74
  CEECAM1           666784     FTC                 45                     2,67E-04         3,73        2,22
  HIST1H4C          682451     FTC                 43                     1,57E-05         −4,45       0,25
  TIE1              743043     FTC                 35                     5,46E-05         4,14        2,52
  SH3RF2            744797     FTC                 22                     5,37E-03         2,82        2,18
  MGC5395           238840     FTC                 15                     5,07E-04         3,55        2,66
  EMX2              365121     FTC                 14                     6,95E-03         −2,73       0,51
  LRRC28            26519      FTC                 13                     1,51E-03         −3,23       0,40
  GFRA3            2716748     FTC                 11                     4,52E-03         2,88        1,93
  TTC19             136366     GD                  72                     1,57E-04         3,87        1,87
  ATP6V1G2          726424     GD                  61                     1,91E-04         3,82        2,22
  IMAGE:23817       23817      GD                  61                     3,65E-04         −3,64       0,52
  IMAGE:178161      178161     GD                  52                     6,99E-04         3,46        2,53
  BDKRB2            665674     GD                  50                     6,16E-03         2,78        2,15
  IMAGE:744385      744385     GD                  48                     1,37E-02         2,49        1,70
  LOC150837         258698     GD                  47                     5,84E-04         3,51        1,81
  SSX1              262894     GD                  47                     5,97E-04         3,50        1,76
  DHX57             24623      GD                  46                     1,69E-03         −3,19       0,59
  RAI14             731711     GD                  46                     8,19E-03         2,68        1,56
  IMAGE:180851      180851     GD                  45                     5,36E-03         −2,82       0,61
  MGC5566           53119      GD                  43                     1,74E-03         3,18        1,85
  D21S2056E         740140     GD                  36                     2,44E-03         3,08        1,72
  IMAGE:729489      729489     GD                  31                     1,28E-03         3,28        2,95
  KIAA1737          122063     GD                  29                     1,78E-03         3,18        1,67
  MLH3              250771     GD                  21                     8,59E-03         2,66        1,59
  IMAGE:53081       53081      GD                  18                     3,35E-03         2,98        1,77
  TERF1             135773     GD                  16                     2,81E-02         2,22        1,45
  DCXR              724596     GD                  15                     3,39E-03         −2,97       0,61
  IMAGE:136686      136686     GD                  15                     6,29E-02         1,87        1,48
  FLJ11127          668625     MNG                 88                     2,30E-06         4,90        1,54
  RODH              471641     MNG                 83                     1,51E-05         4,46        2,57
  MGC17299          713422     MNG                 59                     6,54E-05         4,10        1,37
  NR2F2             72744      MNG                 57                     3,10E-04         3,69        1,40
  ZNF83             486356     MNG                 50                     3,72E-04         3,64        1,32
  IMAGE:744505      744505     MNG                 43                     2,51E-04         3,74        1,38
  IMAGE:745187      745187     MNG                 42                     1,15E-03         −3,31       0,78
  CAV1              309645     MNG                 41                     3,38E-04         3,66        1,59
  CNTN6             257773     MNG                 41                     2,34E-04         3,76        1,38
  C10orf116         740941     MNG                 40                     2,82E-04         3,71        1,72
  CALM1             594510     MNG                 39                     1,21E-03         −3,30       0,77
  IMAGE:726782      726782     MNG                 39                     3,97E-04         3,62        1,38
  IMAGE:250463      250463     MNG                 28                     6,76E-03         2,74        1,29
  IMAGE:731726      731726     MNG                 28                     3,90E-04         3,62        1,52
  TTC17             665668     MNG                 28                     5,24E-04         3,54        1,31
  PRKCA             768246     MNG                 25                     9,12E-04         −3,38       0,71
  NR4A1            1073288     MNG                 19                     1,88E-03         −3,16       0,64
  PDLIM1            135689     MNG                 14                     9,76E-04         3,36        1,48
  IMAGE:731292      731292     MNG                 11                     2,65E-02         −2,24       0,68
  SLC17A2           207920     MNG                 9                      2,70E-02         −2,23       0,67
  MLL               80688      OTA                 76                     1,00E-07         −8,18       0,55
  ALDH1A3           486189     OTA                 67                     1,00E-07         6,38        1,79
  CLECSF12          258865     OTA                 63                     1,00E-07         7,66        3,51
  IMAGE:485104      485104     OTA                 60                     1,00E-07         7,32        2,25
  DCN               666410     OTA                 49                     1,00E-07         −7,19       0,50
  PROZ              430471     OTA                 47                     1,00E-07         7,05        2,76
  CHRDL2            485872     OTA                 46                     1,00E-07         6,72        1,58
  B3GNTL1           53341      OTA                 39                     9,00E-07         5,10        2,04
  SNRP70            729971     OTA                 39                     1,00E-07         −7,00       0,52
  HSPC159           365045     OTA                 38                     1,00E-07         6,86        1,70
  C4A               724366     OTA                 32                     1,00E-07         −6,30       0,39
  SLC6A8            725877     OTA                 31                     1,00E-07         −7,00       0,23
  OBSCN             730926     OTA                 29                     1,00E-07         6,95        1,55
  IMAGE:731616      731616     OTA                 27                     1,00E-07         6,88        2,42
  DC12              724895     OTA                 24                     1,00E-07         6,67        1,71
  UBA52             530069     OTA                 16                     4,40E-06         −4,75       0,29
  KCNQ2             179534     OTA                 14                     1,00E-07         6,43        1,77
  HCNGP             365934     OTA                 11                     1,92E-05         4,40        1,40
  C9orf72           726849     OTA                 10                     4,40E-06         −4,75       0,69
  GNAI1             753215     OTA                 6                      8,90E-06         4,59        1,48
  SDHA              40304      OTC                 95                     1,00E-07         6,29        3,16
  DNALI1            782688     OTC                 72                     1,00E-07         −5,53       0,24
  IMAGE:382423      382423     OTC                 50                     1,50E-06         5,00        3,52
  ATP11C            667991     OTC                 47                     2,30E-05         4,36        2,17
  C1QBP             173371     OTC                 46                     2,70E-06         4,86        2,47
  DCN               666410     OTC                 43                     6,80E-06         −4,65       0,29
  MT1F              78353      OTC                 41                     3,70E-06         −4,79       0,16
  KIAA0543          175080     OTC                 38                     9,15E-05         4,01        2,03
  FBXO46            471664     OTC                 37                     1,67E-05         4,44        2,85
  CD33             1917430     OTC                 35                     1,06E-05         4,55        3,71
  TH                813654     OTC                 32                     8,32E-04         3,41        1,95
  IMAGE:742061      742061     OTC                 31                     1,99E-05         4,39        2,73
  IDH3B             723755     OTC                 27                     1,90E-05         4,41        2,27
  IMAGE:359454      359454     OTC                 23                     1,31E-05         −4,50       0,27
  SST               39593      OTC                 23                     1,34E-03         3,26        1,81
  DHRS6             364412     OTC                 20                     4,03E-04         −3,61       0,48
  IMAGE:136933      136933     OTC                 19                     6,25E-03         2,77        2,19
  TPM2              740620     OTC                 18                     1,59E-05         −4,45       0,30
  TM7SF3            666928     OTC                 14                     3,58E-04         3,65        2,00
  PREB              740347     OTC                 5                      1,29E-02         −2,51       0,33
  LRRIQ2            487152    OTUM                 59                     1,29E-04         3,92        2,01
  LRRC28            26519     OTUM                 53                     2,04E-04         −3,80       0,43
  NDUFC1            796513    OTUM                 53                     2,65E-03         −3,05       0,61
  NUMBL            1855110    OTUM                 53                     2,94E-04         −3,70       0,56
  IMAGE:667527      667527    OTUM                 48                     2,31E-04         3,77        2,45
  MAK               382002    OTUM                 43                     3,71E-04         3,64        2,14
  PCGF4             740457    OTUM                 43                     3,06E-04         3,69        2,61
  IFITM3            713623    OTUM                 42                     1,74E-02         2,40        1,63
  CLGN             1049033    OTUM                 40                     1,52E-03         3,23        1,86
  DEFB1             665086    OTUM                 40                     9,17E-04         3,38        2,79
  IMAGE:669098      669098    OTUM                 35                     9,47E-04         3,37        1,85
  GNAS              382791    OTUM                 31                     6,58E-04         3,47        2,75
  PTTG1             742935    OTUM                 29                     7,53E-03         −2,71       0,52
  USP14             376462    OTUM                 28                     9,21E-03         −2,64       0,65
  SNF7DC2           730401    OTUM                 25                     1,36E-02         2,49        1,51
  C21orf84          730814    OTUM                 19                     1,24E-03         3,29        2,08
  TCTE3             136862    OTUM                 19                     2,48E-02         −2,27       0,69
  TH                813654    OTUM                 19                     3,81E-02         −2,09       0,69
  BAK1              235938    OTUM                 16                     1,12E-03         3,32        1,80
  PAX6              230882    OTUM                 12                     1,28E-02         −2,52       0,66
  CDH3              359051     PTC                 99                     1,00E-07         9,16        3,95
  DPP4              343987     PTC                 98                     1,00E-07         8,72        4,22
  CLDN1             594279     PTC                 86                     1,00E-07         7,88        8,98
  SEP-02            729542     PTC                 83                     2,60E-01         1,13        1,20
  ABCC3             208097     PTC                 74                     1,00E-07         6,30        3,48
  ECM1              301122     PTC                 67                     1,00E-07         8,24        6,00
  TSC               745490     PTC                 60                     1,00E-07         7,70        4,65
  QPCT              711918     PTC                 57                     1,00E-07         7,27        3,36
  ADAMTS9           376153     PTC                 48                     6,40E-06         4,66        1,95
  IMAGE:687667      687667     PTC                 48                     1,00E-07         7,10        3,74
  SLPI              378813     PTC                 46                     1,00E-07         7,03        2,98
  MATN1            1624260     PTC                 43                     1,00E-07         −6,74       0,42
  CITED1            265558     PTC                 40                     1,00E-07         6,84        4,88
  CCND1             324079     PTC                 38                     1,00E-07         6,39        2,55
  IMAGE:136976      136976     PTC                 23                     1,00E-07         6,15        2,11
  PET112L           743125     PTC                 20                     1,00E-07         6,27        1,96
  DAF               627107     PTC                 16                     1,00E-07         5,68        1,89
  GSS               140405     PTC                 7                      1,00E-07         5,73        2,05
  CASP3             823680     PTC                 5                      6,00E-07         5,20        2,08
  CD9               727251     PTC                 1                      1,45E-05         4,47        1,57
  IMAGE:687667      687667     TUM                 94                     1,00E-07         6,33        3,90
  CREB3L2           136399     TUM                 63                     4,90E-06         −4,73       0,48
  EIF1AY            380394     TUM                 55                     4,02E-05         −4,22       0,57
  DJ462O23.2        738970     TUM                 51                     1,64E-05         4,44        1,63
  CITED1            265558     TUM                 49                     1,21E-05         4,51        3,53
  KLF1              208991     TUM                 46                     3,72E-05         −4,24       0,43
  SNCB              50202      TUM                 45                     4,68E-05         4,18        1,99
  FLJ10748          726830     TUM                 44                     4,24E-05         4,21        1,71
  ANK2             2139315     TUM                 43                     1,31E-03         3,27        1,68
  IGFBP3            269873     TUM                 39                     9,68E-05         4,00        2,06
  WDR1              714196     TUM                 37                     2,06E-04         −3,80       0,65
  IFNAR2            123950     TUM                 36                     2,56E-04         −3,74       0,61
  SCNN1A            741305     TUM                 36                     2,37E-05         −4,35       0,41
  TSC               745490     TUM                 27                     1,95E-04         3,81        2,61
  NBL1              503874     TUM                 24                     2,47E-04         −3,75       0,35
  ETF1              146976     TUM                 18                     6,36E-04         3,48        1,63
  ICOSLG           2074228     TUM                 18                     1,12E-03         3,32        1,55
  NCB5OR            743367     TUM                 15                     2,03E-03         −3,14       0,56
  ZNF415            23939      TUM                 14                     4,94E-03         −2,85       0,63
  KLK2             1102600     TUM                 9                      1,39E-03         −3,25       0,66

AT: autoimmune thyroiditis; FTA: macrofollicular thyroid adenoma; FTAb: microfollicular thyroid adenoma; FTC: follicular thyroid carcinoma; GD, Graves\' disease; MNG: multinodular goiter; OTA: oncocytic thyroid adenoma; OTC: oncocytic thyroid carcinoma; PTC: papillary thyroid carcinoma; TUM: tumor of uncertain malignancy; and OTUM:, oncocytic tumor of uncertain malignancy.

Class prediction from binary and from complete training {#s2b}
-------------------------------------------------------

We compared classifiers defined from many classes, i.e. the entire dataset (complete training), and two classes, i.e. one pathological class *versus* normal thyroid tissue (binary training). The predictive accuracy for the samples of a class, i.e. the positive accuracy, was always higher after binary training than after complete training in the two main datasets ([Figure 2A](#pone-0007632-g002){ref-type="fig"}). With regard to complete training, only two classes in each dataset had similar performances: PTC and AT in the Fontaine dataset, FTC+ and PTC in the Giordano dataset.

![Class prediction of the samples.\
**Panel A** shows the mean positive accuracy of classifiers during intra-dataset cross-validations for the two main datasets, i.e. the Fontaine dataset and the Giordano dataset. Each classifier is composed of 20 genes selected by the Greedy Pairs algorithm and using Diagonal Linear Discriminant Analysis for training and prediction. Some classifiers were trained with samples from the selected class and the normal tissue, i.e. with binary training (black bars). Other classifiers were trained with all the samples of the dataset, i.e. with complete training (gray bars). **Panel B** shows the class prediction of new samples by binary-trained classifiers in the two datasets. All the new samples come from the same dataset and should have been predicted as negative. The negative predictive value which was deduced from binary training (black bars) is compared to observations on the new samples (gray bars). WT: wild type tissue; PTC: papillary thyroid carcinoma; FTA: macrofollicular thyroid adenoma; FTAb: microfollicular thyroid adenoma; MNG, multinodular goiter; FTC: follicular thyroid carcinoma (FTC+: with Pax8/PPARγ translocation; FTC-: without Pax8/PPARγ translocation); OTA: oncocytic thyroid adenoma; OTC: oncocytic thyroid carcinoma; TUM: tumor of uncertain malignancy; OTUM: oncocytic tumor of uncertain malignancy; GD, Graves\' disease; and AT, autoimmune thyroïditis.](pone.0007632.g002){#pone-0007632-g002}

The classifiers defined by complete training in the Fontaine dataset were evaluated in five other thyroid datasets ([Table 4](#pone-0007632-t004){ref-type="table"}). With respect to the positive accuracy computed from intra-dataset cross-validations, the PTC, FTC, FTA and OTC classifiers turned out to be more accurate than expected. The OTA classifier was less accurate than expected, with a value of 0.59 *versus* 0.64, but only one other dataset contained this class of thyroid tissue.

10.1371/journal.pone.0007632.t004

###### Inter-dataset cross-validations. Positive accuracies of the classifiers defined by the Fontaine dataset in five other datasets.

![](pone.0007632.t004){#pone-0007632-t004-4}

  DATASET                   PTC    FTC    FTA    OTC    OTA
  ------------------------ ------ ------ ------ ------ ------
  Giordano *et al*. 2006    0.93   0.40   0.48   0.64   0.59
  Weber *et al*. 2005        \-    0.77   0.96   0.72    \-
  Jarzab *et al*. 2005      1.00    \-     \-     \-     \-
  Reyes *et al*. 2006       1.00    \-     \-     \-     \-
  He *et al*. 2005          1.00    \-     \-     \-     \-

FTA: macrofollicular thyroid adenoma; FTC: follicular thyroid carcinoma; OTA: oncocytic thyroid adenoma; OTC: oncocytic thyroid carcinoma; and PTC: papillary thyroid carcinoma.

Functional analysis of cross-validated differential genes {#s2c}
---------------------------------------------------------

In the two largest datasets containing the main kinds of thyroid lesions [@pone.0007632-Giordano1], [@pone.0007632-Fontaine1], we searched for cross-validated differential genes. The two lists of differential genes had an intersection of 104 genes that separated five gene clusters from the hierarchical clustering of classes shared by the two datasets ([Figure 3](#pone-0007632-g003){ref-type="fig"} and [Table 5](#pone-0007632-t005){ref-type="table"}). The functions and pathways identified were mainly related to oncocytic and papillary tumors (Clusters 1, 3 and 4). Gene ontologies were associated with oxido-reductive mechanisms (Cluster 1, 28 genes), nitrogen metabolism and cell communication (Cluster 3, 17 genes), glucocorticoid receptor signaling and leukocyte extravasation (Cluster 4, 24 genes). A cluster of genes showed a specific profile for tumors of malignant potential, for which the transcriptional factors involved in the primary anabolic and catabolic cell pathways were down-regulated (Cluster 2, 25 genes). However in Cluster 2, the heterogeneous profiles of some classes (FTA) were suspected of containing molecular subgroups whereas the profiles for WT were almost homogeneous. A cluster of 10 genes (Cluster 5) was not clearly specific to the tissue classes as their profiles differed between the two datasets. In the Fontaine dataset, 52% of the cross-validated genes belonged to at least two of the 11 classes of lesion (data not shown).

![Hierarchical clustering of cross-validated differential genes.\
The heatmap shows gene-expression levels in the Fontaine dataset for the tissue classes common to the Giordano dataset (104 genes). Functional enrichments are shown for five identified gene clusters on the right, followed by p-values and the genes involved. The black text represents Level 3 Gene Ontology terms; the blue text represents canonical Ingenuity pathways. Gene profiles of the differential genes reflect the class similarities observed. WT: wild type tissue; PTC: papillary thyroid carcinoma; FTA: macrofollicular thyroid adenoma; FTC: follicular thyroid carcinoma; OTA: oncocytic thyroid adenoma; and OTC: oncocytic thyroid carcinoma.](pone.0007632.g003){#pone-0007632-g003}

10.1371/journal.pone.0007632.t005

###### Cross validated differential genes from the two main datasets (n = 104).

![](pone.0007632.t005){#pone-0007632-t005-5}

  Cluster      Symbol     UGCluster   Clone ID   P-value     P-value
  --------- ------------ ----------- ---------- ---------- ------------
  1            CASP10      Hs.5353     241481    1,00E-07    1,00E-07
  1             CLGN      Hs.86368    1049033    1,00E-07    1,00E-07
  1            DEFB1      Hs.32949     665086    1,00E-07   1,00^E^-07
  1            NTRK2      Hs.494312   2048801    1,00E-07   1,00^E^-07
  1             SDHA      Hs.440475    40304     1,00E-07   1,00^E^-07
  1           HSPC159     Hs.372208    365045    1,00E-07   3,00^E^-07
  1           ALDH1A3     Hs.459538    486189    1,00E-07   8,00^E^-07
  1            PLCG2      Hs.413111    201467    1,00E-07   9,00^E^-07
  1            ARVCF      Hs.370408    40633     1,00E-07   1,50^E^-06
  1             ELK4      Hs.497520    236155    1,00E-07   1,50^E^-06
  1             DCI       Hs.403436    667892    1,00E-07   1,70^E^-06
  1             DIO1      Hs.251415    296702    1,00E-07   3,50^E^-06
  1             CKS2      Hs.83758     725454    2,00E-07   9,00^E^-07
  1             ID1       Hs.504609   1087348    2,00E-07   3,90^E^-06
  1            MRPS11     Hs.111286    471574    4,00E-07   1,00^E^-07
  1          ST6GALNAC2   Hs.592105    823590    6,00E-07   8,00^E^-07
  1            GFPT2      Hs.696497    485085    9,00E-07   1,00^E^-07
  1           PITPNC1     Hs.591185    364436    9,00E-07   2,00^E^-07
  1             HRK       Hs.87247     767779    1,00E-06   1,00^E^-07
  1            MAPRE2     Hs.532824    383868    1,20E-06   1,00^E^-07
  1             DOK5      Hs.656582    25664     1,30E-06   1,00^E^-07
  1           RPS6KA5     Hs.510225    258966    1,40E-06   1,00^E^-07
  1             DCXR       Hs.9857     724596    3,00E-06   1,00^E^-07
  1             ODAM      Hs.143811    364706    3,30E-06   1,00^E^-07
  1             KLK2      Hs.515560   1102600    5,00E-06   1,30^E^-06
  1              F5       Hs.30054     433155    6,60E-06   1,00^E^-07
  1            MFAP3L     Hs.593942    726821    7,60E-06   1,00^E^-07
  1            GALNT7     Hs.548088    381854    1,10E-05   1,00^E^-07
  2            AHNAK      Hs.502756    238840    1,00E-07   1,00^E^-07
  2             APOD      Hs.522555    838611    1,00E-07   1,00^E^-07
  2           CAMK2N1     Hs.197922    173820    1,00E-07   1,00^E^-07
  2             CFD       Hs.155597    666128    1,00E-07   1,00^E^-07
  2            FCGBP      Hs.111732    154172    1,00E-07   1,00^E^-07
  2            FOXO1      Hs.370666    151247    1,00E-07   1,00^E^-07
  2            GLT8D2     Hs.631650    365271    1,00E-07   1,00^E^-07
  2            MATN2      Hs.189445    28584     1,00E-07   1,00^E^-07
  2            PRUNE      Hs.78524     364324    1,00E-07   1,00^E^-07
  2            SLC4A4      Hs.5462     787938    1,00E-07   1,00^E^-07
  2             PAX8      Hs.469728    545475    1,00E-07   3,00^E^-07
  2           HSD17B6     Hs.524513    471641    1,00E-07   1,30^E^-06
  2             HBB       Hs.523443    469549    1,00E-07   2,60^E^-06
  2             APOE      Hs.654439   1870594    1,00E-07   3,70^E^-06
  2            CRABP1     Hs.346950    739193    1,00E-07   4,20^E^-06
  2            ZNF76      Hs.388024    745003    1,00E-07   4,70^E^-06
  2           C20orf19    Hs.187635    366032    1,00E-07   5,00^E^-06
  2            DEPDC6     Hs.112981    669318    2,00E-07   1,00^E^-07
  2            CDH16      Hs.513660    726763    5,00E-07   1,00^E^-07
  2             HBA2      Hs.654744    469647    6,00E-07   1,80^E^-06
  2            SASH1      Hs.193133    31120     1,40E-06   1,00^E^-07
  2            HEXIM1     Hs.15299     342551    2,20E-06   1,00^E^-07
  2             GJA1      Hs.74471     839101    2,30E-06   1,40^E^-06
  2            TIMP3      Hs.644633    501476    4,30E-06   4,80^E^-06
  2            IL11RA     Hs.591088   1101773    5,50E-06   7,00^E^-07
  3            APLP2      Hs.695920    549054    1,00E-07   1,00^E^-07
  3             DCN       Hs.694789    666410    1,00E-07   1,00^E^-07
  3            FRMD4B     Hs.371681    669564    1,00E-07   1,00^E^-07
  3            HMGB2      Hs.434953    884365    1,00E-07   1,00^E^-07
  3           IGF2BP2     Hs.35354     743774    1,00E-07   1,00^E^-07
  3          LOC400451    Hs.27373     667174    1,00E-07   1,00^E^-07
  3            NPAL3      Hs.523442    738970    1,00E-07   1,00^E^-07
  3            PBXIP1     Hs.505806    366042    1,00E-07   1,00^E^-07
  3            PDGFRL     Hs.458573    139242    1,00E-07   1,00^E^-07
  3            PDLIM1     Hs.368525    135689    1,00E-07   1,00^E^-07
  3            PSAT1      Hs.494261    366388    1,00E-07   1,00^E^-07
  3            SF3B1      Hs.632554    739247    1,00E-07   1,00^E^-07
  3            TIAM1      Hs.517228    23612     1,00E-07   1,00^E^-07
  3             TSHR      Hs.160411    565317    1,00E-07   1,00^E^-07
  3           FAM111A     Hs.150651    137454    1,00E-07   4,00^E^-07
  3             CA11      Hs.428446    282587    3,00E-07   1,00^E^-07
  3            HNRPA3     Hs.516539    365349    5,00E-07   2,60^E^-06
  4            ABCC3      Hs.463421    208097    1,00E-07   1,00^E^-07
  4             CDH3      Hs.461074    359051    1,00E-07   1,00^E^-07
  4            CITED1     Hs.40403     265558    1,00E-07   1,00^E^-07
  4            CLDN1      Hs.439060    594279    1,00E-07   1,00^E^-07
  4             DPP4      Hs.368912    343987    1,00E-07   1,00^E^-07
  4            DUSP5       Hs.2128     33285     1,00E-07   1,00^E^-07
  4            NOTCH2     Hs.487360   1641901    1,00E-07   1,00^E^-07
  4             QPCT      Hs.79033     711918    1,00E-07   1,00^E^-07
  4            S100A4     Hs.654444    868577    1,00E-07   1,00^E^-07
  4             SCEL      Hs.534699    668239    1,00E-07   1,00^E^-07
  4             SLPI      Hs.517070    378813    1,00E-07   1,00^E^-07
  4             TESC      Hs.525709    745490    1,00E-07   1,00^E^-07
  4            TIMP1      Hs.522632    162246    1,00E-07   1,00^E^-07
  4            MGAT3      Hs.276808    731060    1,00E-07   8,00^E^-07
  4             MDK       Hs.82045     309009    2,00E-07   1,00^E^-07
  4             BID       Hs.591054    128065    6,00E-07   1,00^E^-07
  4            NRIP1      Hs.155017    38775     6,00E-07   1,00^E^-07
  4            COL8A2     Hs.353001    486204    1,00E-06   1,00^E^-07
  4             MRC2       Hs.7835     235882    1,60E-06   9,00^E^-07
  4            STAT1      Hs.699271    110101    2,10E-06   1,00^E^-07
  4            ARMCX3     Hs.592225    251452    2,40E-06   1,00^E^-07
  4            LAMB3      Hs.497636   1103402    9,90E-06   1,00^E^-07
  4             CD55      Hs.527653    627107    1,30E-05   1,00^E^-07
  5            DUS4L      Hs.97627     726904    1,00E-07   1,00^E^-07
  5            ESRRG      Hs.444225    44064     1,00E-07   1,00^E^-07
  5            ISG20      Hs.459265    740604    1,00E-07   1,00^E^-07
  5             ROR2      Hs.644776   1089025    1,00E-07   1,00^E^-07
  5           S100A11     Hs.417004    143957    1,00E-07   1,00^E^-07
  5            SEMA4D     Hs.655281    210587    1,00E-07   1,00^E^-07
  5             CD58      Hs.34341    2103105    1,00E-07   2,00^E^-07
  5             IRF9       Hs.1706     724588    1,10E-06   3,20^E^-06
  5            MCOLN1     Hs.631858    726156    2,00E-06   2,00^E^-07
  5            ITGB7      Hs.654470   1337232    1,09E-05   2,90^E^-06

Independent validation of selected genes by real-time RT-PCR {#s2d}
------------------------------------------------------------

To test the relevance of some markers selected by cross-validation between the two main datasets, we measured the expression levels of six differential genes, CASP10, CDH16, CLGN, CRABP1, HMGB2 and ALPL2, on 32 new follicular tumor samples, including eight samples each of FTA, FTAb, OTA and FTC ([Figure 4A](#pone-0007632-g004){ref-type="fig"}). For all six genes, the expression levels differentiated between follicular adenomas (macro- and micro-follicular) and follicular carcinomas (t-test, p\<0.05). In all cases except one (CASP10, F-test, p\<0.05), the gene expression level differentiated not only between macro- and micro-follicular adenomas but also between follicular adenomas and oncocytic adenomas, as in the case of CDH16 and CRABP1 genes.

![Gene expression of selected markers.\
Differential expression of 12 genes measured by real-time quantitative RT-PCR on 32 new follicular thyroid tumors (8 FTA, 8 FTAb, 8 OTA and 8 FTC). The upper and the lower limits of each box represent the upper and the lower quartiles, respectively. The bold lines represent medians. The expression of ADAMTS2, CABIN1, ADLH1A3, USP13, NR2F2, KRTHB5, CASP10, CDH16, CLGN, CRABP1, HMGB2 and ALPL2 genes was referred to the β-globin expression level. Significances of differential expression between the classes were assessed by t-tests and those over the classes by F-tests. FTA: macrofollicular thyroid adenoma; FTAb: microfollicular thyroid adenoma; FTC: follicular thyroid carcinoma; and OTA: oncocytic thyroid adenoma.](pone.0007632.g004){#pone-0007632-g004}

To test the relevance of our microarray analysis in identifying subclasses of adenomas, we measured the expression levels of six differential genes from the microfollicular adenoma subclass (ADAMTS2, CABIN1, ALDH13, USP13, NR2F2 and KRTHB5), on the same 32 follicular thyroid samples mentioned above ([Figure 4B](#pone-0007632-g004){ref-type="fig"}). Except for NR2F2 (p\<0.954), all genes were differentially expressed not only between the three subclasses of adenomas (t-test, p\<0.05), but also between the four groups of follicular tumors (F-tests, p\<0.05 for ADAMTS2, CABIN1, ALDH13, USP13; p = 0.06 for KRTHB5).

Mutational status of follicular tumors {#s2e}
--------------------------------------

The mutational status of three genes (TSHR, GNAS and NRAS) was investigated on 59 solitary follicular adenomas (43 from the microarray study, and 16 from the RT-PCR study) to compare these to the expression profile of FTA samples and evaluate their functional status. To identify the role of the PAX8-PPARG translocation in the expression profile of the FTC class, the rearrangement status for PAX8-PPARG was explored on 11 FTC samples (three samples from the microarray study, and eight samples from the RT-PCR study).

In the follicular adenoma samples, we identified mutations in the TSHR gene in seven of the 59 samples (12%): six of which were macrofollicular adenomas from the microarray study and one was a macrofollicular adenoma from the RT-PCR study. All the mutations were situated in the seventh transmembrane domain of the TSH receptor (from codon 619 to codon 633). Our results are in accordance with the mutational status of the TSH receptor gene described in the literature, especially concerning the macrofollicular subtype [@pone.0007632-Corvilain1]. One macrofollicular adenoma presented a mutation in codon 201 of the GNAS gene. None of the microfollicular adenomas showed TSHR and GNAS mutations in the four exons explored. Five microfollicular adenomas (four from the microarray study, and one from the RT-PCR study) were positive for the NRAS mutation in codon 61.

No PAX8-PPARG translocation was found in any of the FTC samples studied.

Protein expression of selected differential genes in independent samples {#s2f}
------------------------------------------------------------------------

We collected 49 new tissue samples to measure the protein expression of six selected differential genes in the classes common to the two main datasets (FTA, FTC, OTA, OTC, PTC and WT), and also for the AT class as a non-tumoral control ([Figure 5](#pone-0007632-g005){ref-type="fig"}). There was significant differential expression between the classes (F-tests, p\<0.05) for five proteins (SDHA, CLGN, APOD, CRABP1 and TIMP1). The APOE protein was not differentially expressed (p\<0.932). Among the differentially expressed proteins, three had profiles similar to their gene profiles (SDHA, APOD and TIMP1), whereas two proteins (CLGN and CRABP1) showed some differences, as reported in previous studies of selected classes [@pone.0007632-Baris1], [@pone.0007632-Wasenius1]. The expression of the CLGN protein was higher in the FTA and FTC samples, but not in the oncocytic samples, contrary to the gene profile observed. The CRABP1 protein was differentially expressed between the FTA samples compared to the PTC and FTC samples, with a decreased expression of both RNA and protein in the malignant tumors. Considering the appurtenance of this gene to Cluster 2 ([Figure 3](#pone-0007632-g003){ref-type="fig"}), the expression of CRABP1 protein could serve to distinguish between the benign and malignant groups of thyroid tissue.

![Protein expression of selected genes.\
The protein expression of six selected differential genes was measured on 49 new tissue samples. These independent samples represent six tissue classes that are common to the two main datasets (WT, PTC, FTA, FTC, OTA, and OTC). The AT class was added to compare the expression levels with a non-tumoral lesion. Seven samples were used for each class. Protein expression profiles of APOD, CLGN, SDHA, APOE, CRABP1 and TIMP1 are shown by box-plots for the different classes of tissue. Significances of differential expression over the classes were assessed by F-tests. P-values are shown between brackets. WT: wild type tissue; PTC: papillary thyroid carcinoma; FTA: macrofollicular thyroid adenoma; FTC: follicular thyroid carcinoma; OTA: oncocytic thyroid adenoma; and OTC: oncocytic thyroid carcinoma.](pone.0007632.g005){#pone-0007632-g005}

Discussion {#s3}
==========

The clinical diagnosis of thyroid tumors is subject to significant inter- and intra-observer variations [@pone.0007632-Franc1], [@pone.0007632-Lloyd1]. Since 2001, various molecular markers for thyroid tumors have been proposed on the basis of microarray analysis. However, none of these markers has proved satisfactory in clinical practice, possibly because only a small number of thyroid tumor classes were initially taken into account. In our study, we analyzed six publicly available microarray datasets containing 347 thyroid tissue samples and defining as many as 12 classes of thyroid tumors. One of these datasets, the Fontaine dataset generated by our laboratory, comprised about half the total number of samples, including all the differentiated follicular thyroid lesions.

With regard to the 12 classes of thyroid tumor defined, we found that more than half of the 104 relevant and cross-validated differential genes were also related to other classes, such as AT, GD, TUM, FTAb, which were not shared by the two main datasets, i.e. the Giordano dataset and the Fontaine dataset. This may have affected the relevance of the signature in the classification of the follicular pathologies, explaining the low percentage of genes common to the two classifiers. Although the genes were selected from different sets of classes, discrepancies of some gene profiles, for example in Cluster 5, may be related to incomplete microarray platform compatibility or to differential cellular environment. Interestingly, most of the genes in Cluster 5 were involved in the process of vascular endothelial cell expansion[@pone.0007632-Ao1]--[@pone.0007632-Taylor1], which may represent the stromal reaction. Despite the small number of FTC and OTC samples and the microarray platform being restricted to 9,216 probes, our classifier was able to validate the classification of PTC, FTC, FTA and OTC on five other datasets ([Table 3](#pone-0007632-t003){ref-type="table"}). This demonstrated the relevance of our approach to the molecular classification of the main types of differentiated follicular thyroid pathology.

Unsupervised analysis of the class signatures showed a separation into three groups corresponding to benign, malignant, and oncocytic thyroid tumors ([Figure 1](#pone-0007632-g001){ref-type="fig"}). The pairwise distinctions of benign/normal and malignant tumors were consistent with published reports, as in the case of PTC and FTA [@pone.0007632-Finley1]. The surprising proximity of the FTC and FTA classes in the Giordano dataset has already been discussed [@pone.0007632-Lacroix1]. This could be related to the high homogeneity in the expression profiles of the FTC samples, which were positive for the PAX8-PPARG rearrangement and significantly related to the malignant profile of the PTC samples. Thus, the clustering of the FTC- and FTA classes appears to be related more to their heterogeneous expression profiles rather than to their tendency to tumoral behavior. These results strongly suggest the existence of molecular subclasses for the FTA and FTC- samples. Interestingly, the FTC samples in the Fontaine dataset, included in the malignant group, were negative for the PAX8-PPARG translocation.

Although the histologic diagnosis of oncocytic follicular tumors presents few problems, the two latest WHO classifications have debated whether these tumors should be considered as an independent class of tumors or as a variant of follicular tumors. This question is still relevant in view of the recent results of miRNA profiling that clearly revealed the segregation of oncocytic tumors from other conventional follicular tumors [@pone.0007632-Nikiforova2]. According to their specific gene-expression profiles as well as their mutational status for RAS and PAX8-PPARγ genes [@pone.0007632-Nikiforova1], oncocytic tumors should be considered as distinct from the other follicular tumors. The role of the "oncocytic group" signature in the appropriate classification of benign and malignant tumors is debatable. Considering the mitochondrial richness of follicular thyroid tumors, this signature may highlight the metabolic changes during tumorigenesis. Little is known about the etiology of oncocytomas but their signature is composed of numerous mitochondrial and metabolic genes, and the role played by these genes in tumor aggressivity has not yet been established [@pone.0007632-Nikiforova1], [@pone.0007632-Baris1]. Interestingly, we found that microfollicular adenomas (FTAb) were related by their molecular profiles to oncocytic adenomas as well as to carcinomas. Relationships between thyroid metabolism and microfollicular lesions have been explored [@pone.0007632-Nucera1], but never in the context of mitochondrial functions. However, in a recent study, the galectin-3 profile associated with FTAb was reported to be related to its role in the regulation of mitochondrial stability [@pone.0007632-Fukumori1]. Galectin-3 has been also involved in thyroid tumorigenesis through its anti-apoptotic activity [@pone.0007632-Savin1]. Thus, the malignant potential of FTAb is still under discussion [@pone.0007632-Schmid1].

Evaluation of the performance of the classifiers used showed that poor performance was associated with the FTA subclasses in the two main datasets. In our study, the functional status of the FTA samples may have influenced the performance of the classifiers in discriminating true FTA from hyperfunctioning nodules. Only 12% of macrofollicular adenomas presented mutations in the TSH receptor or GNAS genes. These results correlated on microarray analysis with the expression profile of several genes previously associated with the hyperfunctional status of nodules [@pone.0007632-Wattel1]. Even though our FTA group represents a mix of adenomas in terms of functional status, the signature of follicular adenoma defined by our classifier are involved in other processes than iodine uptake and thyroid hormone secretion. As the selected genes are mainly associated to cell metabolism (CABIN1, CAMK2A, DAP, PDK4), signal transduction (ASGR1, PLXNB2, TBC1, PLCG1) and cell adhesion (COL18A1), we believe that the FTA signature we propose can discriminate true FTA from other follicular thyroid tumors. The relevance of constructing subclasses of follicular adenomas was tested on six cross-validated markers and six specific markers from our own analysis ([Figure 4](#pone-0007632-g004){ref-type="fig"}). Five specific markers enabled us to segregate micro- and macro-follicular adenomas from oncocytic adenomas and minimally invasive follicular carcinomas, while only one of the six cross-validated markers showed the same performance. Distinguishing between subclasses of adenoma allowed the identification of relevant molecular markers of follicular adenomas. These markers had never been differentially selected during previous microarray analyses of thyroid tumors. However, three of the markers (ADAMTS2, ALDH1A3 and CABIN1) had been proposed as prognostic markers for the recurrence of epithelial tumors [@pone.0007632-Carinci1]--[@pone.0007632-Watanabe1].

The observation of six protein profiles highlights the difficulty of proposing immunomarkers for clinical practice. However, some markers may be relevant for the classification of differentiated follicular pathologies (FTA, FTC, PTC, OTA and OTC). It has been suggested that APOD, which has a specific protein profile for FTC and PTC, may modify the proliferative activity of cancer cells [@pone.0007632-Soiland1]. The differential expression of the folding protein calmegin (CLGN) with FTA and FTC samples may be associated with a difference in the abundance of the protein, as recently described in thyroid tumors [@pone.0007632-NeteaMaier1]. Furthermore, increasing the number of thyroid tumor classes has revealed new aspects of some of the markers. Thus, TIMP1 and CRABP1 were not selected by our classifier but figured in the intersecting differential gene lists. Our data clearly questioned the relevance of TIMP1 as a marker of thyroid cancer. Since high protein levels were observed in the AT and PTC classes, TIMP1 expression may be more closely related to the frequently described lymphocytic infiltration in PTC [@pone.0007632-Delys1]. Quantitative RT-PCR analysis on new follicular samples confirmed the upregulation of CRABP1 expression in all the adenomas as compared to follicular carcinomas. Underexpression of CRABP1 mRNA was relevant in distinguishing the FTC as well as PTC classes, as reported previously [@pone.0007632-Hawthorn1], [@pone.0007632-Huang2]. However, our results differed at the protein level compared to a study on cold thyroid nodules where both the expression of CRABP1 mRNA and the protein were downregulated compared to normal surrounding tissue [@pone.0007632-Eszlinger3]. As our FTA samples were mostly non-functioning nodules, we postulate that this difference in protein level may be due to the histological class studied, macrofollicular adenomas in the Fontaine dataset, as opposed to the mix of follicular adenomas and adenomatous nodules in the other study. While all these markers can be used to complement current markers [@pone.0007632-Barroeta1], the exploration of a large panel of protein markers to improve the differential diagnosis may rapidly become more cumbersome and less relevant than the study of the expression profile of selected genes, especially in the case of suspicious nodular thyroid lesions.

In conclusion, diagnostic tools defined on the basis of thyroid microarray data are more relevant when many samples and tissue classes are used, especially with the inclusion of oncocytic tumors. Our study has revealed additional potentially useful gene and protein markers allowing the classification of several thyroid pathologies. However, to identify early events of transformation, these markers should be viewed in the context of the biological processes in which they participate. We therefore believe that dedicated gene-expression profiling offers the most powerful method of identifying gene groups that correlate to nodular growth, thyroid dedifferentiation or malignancy, taking into account the potential contamination by other cell types such as activated lymphocytes. In this context, the molecular classification of microfollicular adenomas on fine needle aspiration biopsies should have a direct impact in the management of such tumors.

Materials and Methods {#s4}
=====================

Samples and microarray datasets {#s4a}
-------------------------------

We analyzed gene-expression data from six microarray datasets containing up to 12 classes of differentiated thyroid pathologies and normal thyroid tissue. The FTA samples were divided into two subclasses according to their follicular architecture, FTA (macrofollicular) and FTAb (microfollicular). The dominant nodule within the multinodular goiter (MNG) was investigated to explore the incidence of genetic or environmental events on the molecular signature of the class of follicular adenoma. When possible, the FTC class was also divided into two subclasses, FTC+ and FTC-, defined respectively by the presence or absence of the PAX8/PPARγ translocation in the samples. Atypical (TUM) and oncocytic features (OT) were individualized on criteria specified elsewhere [@pone.0007632-Fontaine1], [@pone.0007632-Baris1]. We also explored non-tumoral lesions such as those in Graves\' disease (GD) and autoimmune thyroiditis (AT) to identify the immunological environment of the tumoral samples. This study is based on the Fontaine dataset generated by our laboratory, which comprises 12 subclasses containing a total of 166 anonymized human thyroid tissues. The five other datasets, particularly the Giordano dataset with 7 subclasses, were used to cross-validate the results of the molecular classification, the classifiers, and the functional analysis of differential genes [@pone.0007632-Giordano1], [@pone.0007632-He1]--[@pone.0007632-Weber2]. One dataset (Reyes *et al*.) has not yet associated citation. Details of the six datasets, containing a total of 347 samples, are summarized in [Table 1](#pone-0007632-t001){ref-type="table"}.

The Fontaine and the Giordano datasets are referred as the main datasets. All the datasets, generated by various microarray platforms ([Table 1](#pone-0007632-t001){ref-type="table"}), are publicly available. The Fontaine dataset (GSE6339), the He dataset (GSE3467) and the Reyes dataset (GSE3678) are hosted by the Gene Expression Omnibus (GEO) database of the U.S. National Center for Biotechnology Information. The Weber dataset was downloaded from European Bioinformatics Institute ArrayExpress database (E-MEXP-97). The two other datasets were downloaded from the authors\' websites: the Giordano dataset (<http://dot.ped.med.umich.edu:2000/pub/PPARG/index.html>) and the Jarzab dataset (<http://www.genomika.pl/thyroidcancer/PTCCancerRes.html>).

Data analysis {#s4b}
-------------

For the Fontaine dataset generated in our laboratory, hierarchical clustering of the data was computed on log-transformed, median gene-centered and normalized data as described elsewhere [@pone.0007632-Fontaine1]. Normalized data from the Giordano and Jarzab datasets were downloaded from the authors\' websites. For the remaining datasets, raw data were downloaded from the GEO or Array Express databases and normalized with BRB Array Tools v3.7.0b1 developed by Dr. Richard Simon. Since the data originated from three different but one-color platforms, global normalization to the median was used to center the gene-expression values in each array. Genes showing minimal variation across the set of arrays were excluded from the analysis (log-intensity variation P-value\>0.15). Hierarchical clustering was done on centered genes by using the centered correlation distance and an average linkage method. Robustness and discrepancy indices were computed from 10,000 data perturbations.

For the two largest datasets [@pone.0007632-Giordano1], [@pone.0007632-Fontaine1], we identified genes that were differentially expressed among the classes by using a multivariate 10,000-permutation test, to provide 95% confidence that the number of false discoveries did not exceed 1. Although F-statistics were used for each gene, the multivariate permutation test is non-parametric and does not require the assumption of Gaussian distributions. Functional enrichments in gene clusters were defined at 5% risk for Level 3 Gene Ontology terms by Fatigo tools (adjusted P-values, [www.fatigo.bioinfo.cipf.es](http://www.fatigo.bioinfo.cipf.es) [@pone.0007632-AlShahrour1]) as compared to the whole genome, and for canonical pathways by Ingenuity Pathway Analysis tools as compared to the Ingenuity Pathways Knowledge database ([www.ingenuity.com](http://www.ingenuity.com)).

Classifiers were defined for each pathological class and trained either *versus* the wild type class (binary training) or the entire dataset (complete training). Twenty genes were selected by the Greedy Pairs algorithm, and Diagonal Linear Discriminant Analysis (DLDA) was used for training and sample [@pone.0007632-Dudoit1]. Intra- and inter-dataset cross-validations were done by the 0.632+ method and DLDA respectively [@pone.0007632-Efron1]. Since the classical accuracy coefficient is biased in large datasets containing unbalanced class sizes, we preferred to use the positive accuracy coefficient defined as the geometric mean of the sensitivity (i.e. the proportion of true positives in the samples belonging to the targeted class in the entire datasets) and the positive predictive value (i.e. the proportion of true positives in the samples belonging to the targeted class) [@pone.0007632-Kubat1].

Quantitative RT-PCR analysis {#s4c}
----------------------------

An independent set of 32 follicular tumors, comprising 8 minimally invasive FTC and 24 follicular adenoma (8 OTA, 8 FTA and 8 FTAb), were subjected to real-time quantitative RT-PCR to test the relevance of several selected markers. The anonymized samples were obtained from the Department of Pathology of the University Hospital of Angers, France.

Total RNA was isolated using the TRIzol reagent (Invitrogen, Paisley, UK). RNA integrity was determined using a Bio-Analyzer 2100 (Agilent Technologies, Waldbronn, Germany). Reverse transcription was performed on 1 µg of RNA with Advantage RT-for-PCR kit (Clontech Laboratory, Palo Alto, CA, USA) following the manufacturer\'s recommendations. Real-time quantification was performed in a 96-well plate using the IQ SYBR Green supermix and Chromo4 (Biorad, Hercules, CA, USA) with the recommended protocol. Twelve genes were explored for their expression levels: CASP10, CDH16, CLGN, CRABP1, HMGB2, ALPL2, ADAMTS2, CABIN1, ALDH1A3, USP13, NR2F2 and KRTHB5. Data were normalized to the β-globin expression level. The significance of differential expression between classes was assessed by t-tests and that over the classes by F-tests. The primer sequences used in this study are specified in [Table 6](#pone-0007632-t006){ref-type="table"}.

10.1371/journal.pone.0007632.t006

###### Primer sequences used for real-time quantitative RT-PCR.

![](pone.0007632.t006){#pone-0007632-t006-6}

  Gene                    Forward Sequence                   Reverse Sequence
  -------------- ---------------------------------- ----------------------------------
  **ADAMTS2**     5′-GGG-AAG-GAG-CAC-GTA-CAG-AA-3′   5′-CGT-GAT-CGT-GGT-ATT-CAT-CG-3′
  **ALDH1A3**     5′-TCT-CGA-CAA-AGC-CCT-GAA-GT-3′   5′-GTC-CGA-TGT-TTG-AGG-AAG-GA-3′
  **APLP2**       5′-GCT-GTC-GTT-CCG-GTT-ATG-TT-3′   5′-GAG-GGT-CTC-TCA-CGT-GCT-TC-3′
  **CABIN1**      5′-AGG-CCC-TGG-AGG-TGT-ACT-TT-3′   5′-CCA-GCT-GAA-GAG-TGG-GAG-TC-3′
  **CASP10**      5′-TCT-CAG-GAT-CAC-TGG-GCT-CT-3′   5′-ATG-AAG-GCG-TTA-ACC-ACA-GG-3′
  **CDH16**       5′-CAA-GTC-ATG-AGG-TGG-TGG-TG-3′   5′-GAT-GGT-CAG-CAG-GAA-AGA-GC-3′
  **CLGN**        5′-CAA-TGG-ACC-TGG-AAG-AGG-AA-3′   5′-TGA-CTT-TAT-CGG-CCC-ATC-TC-3′
  **CRABP1**      5′-CAG-GAC-GGG-GAT-CAG-TTC-TA-3′   5′-CGC-CAA-ACG-TCA-GGA-TAA-GT-3′
  **HMGB2**       5′-AGA-GGC-TGA-GGA-TTG-CGT-TA-3′   5′-GGG-GTC-TCC-TTT-ACC-CAT-GT-3′
  **KRTHB5**      5′-AGC-TCT-CAG-GGA-CAA-GAC-CA-3′   5′-AAC-AGG-TTA-GCC-CAG-AAG-CA-3′
  **NR2F2**       5′-TGC-CTG-TGG-TCT-CTC-TGA-TG-3′   5′-ATA-TCC-CGG-ATG-AGG-GTT-TC-3′
  **USP13**       5′-GAC-CTG-CGA-GAA-AAC-CTC-TG-3′   5′-CAG-GAG-TGA-TGG-TTC-CCA-GT-3′
  **β-GLOBIN**    5′-CAA-CTT-CAT-CCA-CGT-TCA-CC-3′   5′-ACA-CAA-CTG-TGT-TCA-CTA-GC-3′

Detection of mutations and PAX8-PPARG rearrangement {#s4d}
---------------------------------------------------

The mutational status for the TSHR, GNAS and NRAS genes was determined for all the FTA and FTAb explored in studies by microarray (26 FTA and 17 FTAb) and RT-PCR (8 FTA and 8 FTAb). DNA was isolated from frozen tissues during the guanidium isothiocyanate procedure (TRIzol Reagent, Invitrogen Life Technologies). Exon 2 of the NRAS gene was amplified using primer sequences described elsewhere[@pone.0007632-Vasko1]. Exons 9 and 10 of the TSH receptor gene, and exons 8 and 9 of the Gs alpha gene were amplified using primer sequences previously specified [@pone.0007632-Bourasseau1]. PCR were performed on 5 µl DNA with the HotGoldstar DNA polymerase (Eurogentec, Seraing, Belgium) according to the manufacturer\'s recommendations. Amplified fragments were purified and directly sequenced on a CEQ 8000 apparatus, using the CEQ DTCS Quick Start Kit (Beckman Coulter, Fullerton, CA, USA) following the manufacturer\'s instructions.

The presence of the PAX8-PPARG translocation was evaluated as described elsewhere [@pone.0007632-Kroll1], on the three FTC samples in the microarray study and the eight FTC samples in the RT-PCR study. Quantification, degradation and DNA contamination of RNA were assessed using an RNA 6000 Nano Assay kit (Agilent Technologies, Palo Alto, CA, USA). After reverse transcription, we looked for the translocation in 5 µl cDNA, using primer sequences previously specified [@pone.0007632-Giordano1] and the HotGoldstar DNA polymerase (Eurogentec, Seraing, Belgium) according to the manufacturer\'s recommendations.

Dot blot analysis {#s4e}
-----------------

Two micrograms of protein corresponding to the TRIzol fraction of 49 independent and anonymized thyroid tissues were spotted onto nitrocellulose membranes at room temperature, using a Dot Blot apparatus (Biorad, Hercules, CA, USA) following the manufacturer\'s recommendations. These tissues, provided by the Department of Pathology of the University Hospital of Angers, differed from those used for the microarray and RT-PCR studies. Six groups of thyroid pathologies were defined according to WHO cytological criteria: AT, FTA, FTC, PTC, OTA and OTC and compared to normal thyroid tissue (WT). Seven samples were tested from each group and the assays were performed in duplicate. Seven primary antibodies (all from Abcam, Cambridge, UK) were used at specific dilutions: 1/750 for TIMP1, 1/1000 for APOD, SDHA, CLGN, CRABP1 and APOE, and 1/5000 for α-tubulin as a control. Peroxidase anti-rabbit or anti-mouse secondary antibodies were revealed using the ECL Plus reagent kit (ECL, Amersham, Chalfont, UK). Spots were quantified on a GelDoc XRS apparatus using Quantity One software (Biorad) and expressed in terms of the control value. Significances of differential expression over the classes were assessed by F-tests.
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